ArticleBMC ophthalmology2026
Reactivation of retinopathy of prematurity after intravitreal bevacizumab: incidence, risk factors, and retreatment requirements.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the incidence and risk factors of reactivation following intravitreal bevacizumab (IVB) treatment for retinopathy of prematurity (ROP) and to determine which cases required additional treatment.
methodsA retrospective cohort study was conducted including 62 premature infants (119 eyes) diagnosed with type 1 ROP or aggressive ROP (A-ROP) who received IVB monotherapy between September 2021 and July 2024. Demographic and clinical parameters such as gestational age, birth weight, disease zone and stage, duration of oxygen therapy, and timing of IVB administration were analyzed. Reactivation and retreatment rates were compared to identify potential risk factors.
resultsReactivation occurred in 36 eyes (30.3%), and 31 of these eyes (86.1%) required additional treatment. The mean gestational age and birth weight in reactivated eyes were 24.4 ± 1.2 weeks and 643 ± 149 g, respectively. Reactivation was significantly associated with lower gestational age (p < 0.001), lower birth weight (p < 0.001), longer pre- and post-IVB oxygen therapy (p = 0.006 and p < 0.001), zone 1 disease (p < 0.001), and the presence of A-ROP (p < 0.001). Reactivation developed on average 9.4 weeks after IVB administration. Female infants showed a higher proportion of treatment-requiring reactivation (p = 0.031).
conclusionsReactivation following IVB therapy is common among infants with low gestational age, low birth weight, prolonged oxygen exposure, and aggressive or zone 1 disease. Although most reactivations required retreatment, some resolved spontaneously, highlighting the importance of individualized and extended post-treatment monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.